Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...194195196197198199200201202203204...208209»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Enrollment open, Metastases:  A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers (clinicaltrials.gov) -  Mar 20, 2018   
    P2,  N=38, Recruiting, 
    Trial completion date: Jun 2021 --> Nov 2019 | Trial primary completion date: Dec 2020 --> May 2019 Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck (clinicaltrials.gov) -  Mar 19, 2018   
    P2,  N=68, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> May 2018 | Trial primary completion date: Dec 2018 --> Dec 2017
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
    Enrollment closed:  Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer (clinicaltrials.gov) -  Mar 14, 2018   
    P2,  N=40, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> May 2018 | Trial primary completion date: Dec 2018 --> Dec 2017 Recruiting --> Active, not recruiting
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients (clinicaltrials.gov) -  Mar 12, 2018   
    P1,  N=49, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=24 --> 49 | Trial completion date: Aug 2018 --> May 2019 | Trial primary completion date: Dec 2017 --> Nov 2018
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma
    New trial:  Improving REsectability in Pancreatic NEoplasms (IRENE) (clinicaltrials.gov) -  Mar 9, 2018   
    P=N/A,  N=14, Recruiting, 
  • ||||||||||  AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Trial primary completion date:  A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 5, 2018   
    P1,  N=30, Recruiting, 
    Recruiting --> Active, not recruiting | N=24 --> 49 | Trial completion date: Aug 2018 --> May 2019 | Trial primary completion date: Dec 2017 --> Nov 2018 Trial primary completion date: Jan 2018 --> Oct 2018
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
    Trial completion, Trial completion date, Trial primary completion date:  The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML (clinicaltrials.gov) -  Feb 27, 2018   
    P3,  N=400, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Jul 2017 --> Jul 2017 Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jun 2017 | Trial completion date: Sep 2016 --> Dec 2017
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    New P2 trial:  Apatinib for Advanced Biliary Carcinoma (clinicaltrials.gov) -  Feb 9, 2018   
    P2,  N=55, Recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker:  A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) (clinicaltrials.gov) -  Feb 7, 2018   
    P2,  N=118, Recruiting, 
    Recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2018 --> Dec 2018 | Trial completion date: Aug 2018 --> Jun 2019 | Initiation date: Mar 2017 --> Mar 2017
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, Trial initiation date:  A Study To Test The Effect Of Apatinib On P450 Enzymes (clinicaltrials.gov) -  Feb 7, 2018   
    P1,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2018 --> Dec 2018 | Trial completion date: Aug 2018 --> Jun 2019 | Initiation date: Mar 2017 --> Mar 2017 Not yet recruiting --> Recruiting | Initiation date: Aug 2017 --> Aug 2017
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Phase classification, Enrollment change, Trial initiation date, Trial primary completion date:  LANCET: Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer (clinicaltrials.gov) -  Feb 6, 2018   
    P1b,  N=40, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Aug 2017 --> Aug 2017 Phase classification: P2 --> P1b | N=60 --> 40 | Initiation date: Jan 2018 --> Apr 2018 | Trial primary completion date: Aug 2019 --> Dec 2019
  • ||||||||||  remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
    Trial primary completion date:  A Phase ?a Study of Remimazolam Tosylate in Healthy Volunteers (clinicaltrials.gov) -  Jan 31, 2018   
    P1,  N=64, Completed, 
    Phase classification: P2 --> P1b | N=60 --> 40 | Initiation date: Jan 2018 --> Apr 2018 | Trial primary completion date: Aug 2019 --> Dec 2019 Trial primary completion date: Oct 2013 --> Jun 2014
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open:  Phase I Study of the Combination of Apatinib and POF (clinicaltrials.gov) -  Jan 26, 2018   
    P1,  N=18, Recruiting, 
    N=68 --> 35 | Trial primary completion date: Dec 2019 --> Dec 2018 Not yet recruiting --> Recruiting